Archives: Search / 2016 / 2015 / 2014 / 2013 / 2012

2014 Archives

11/17/2014

Neuralstem NSI-189 Phase Ib Major Depression Disorder Neurogenic Biomarker Data Presented At The CNS Summit

Depression Biomarker Analysis Shows NSI-189 is Rapidly and Persistently Efficacious

11/10/2014

Neuralstem Announces Publication Of Long Term Cell Survival From Phase I NSI-566 ALS Study In The Journal "Annals Of Clinical And Translational Neurology"

Study Concludes NSI-566 Cells Survived for up to 2.5 Years After Transplantation

11/07/2014

Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update

10/23/2014

Neuralstem Alzheimer's Disease Animal Data Presented At The Congress Of Neurological Surgeons Annual Meeting

10/09/2014

First Patient Treated In Neuralstem Phase I Spinal Cord Injury Stem Cell Trial Through The UC San Diego Sanford Stem Cell Clinical Center

NSI-566 to be Tested in Four Patients with Chronic Spinal Cord Injury

09/22/2014

Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data

Some Patients Continue to Show Slowed Disease Progression or Improvement Three Years Post-Transplant

09/05/2014

Neuralstem President And CEO To Present At The 2014 Rodman & Renshaw Annual Global Investment Conference

Live Webcast on Wednesday, September 10, at 2:55 p.m. EST

08/08/2014

Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update

08/04/2014

Final Patient Treated In Neuralstem Phase II ALS Stem Cell Trial

06/30/2014

Neuralstem Added To Russell 3000 Index

06/25/2014

Neuralstem's NSI-189 Novel Neurogenic Compound Shows Significant Effect In Major Depressive Disorder

Cognitive Deficit and Depression Symptoms Improve Significantly, Trial Data Shows

06/19/2014

Neuralstem NSI-189 Select Data To Be Presented At Neuropsychopharmacology Congress

06/18/2014

Neuralstem Final Phase I Depression Data Presented At The American Society Of Clinical Psychopharmacology Annual Meeting

05/23/2014

Neuralstem Depression Trial Data to Be Presented at The American Society of Clinical Psychopharmacology Annual Meeting

05/16/2014

Neuralstem CEO, Richard Garr, to Present at World Stem Cells & Regenerative Medicine Congress and Give Update on Trials

05/12/2014

Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update

05/08/2014

Neuralstem Appoints Sandford Drexel Smith, Former Genzyme Executive Vice President, To Board Of Directors

04/16/2014

Neuralstem Spinal Cord Injury Stem Cell Trial Approved To Commence At University Of California, San Diego

NSI-566 to be Tested in Patients with Chronic Spinal Cord Injury

04/07/2014

Neuralstem Principal Investigator, Dr. Eva Feldman, To Present Published ALS Trial Phase I Data At Medical Conference

Will Also Present Update on Ongoing Phase II Trial

03/28/2014

First Study To Validate Cell Survival and Functionality in Brain, Improvement Dose Dependent

03/17/2014

Final Results Of Neuralstem Phase I Stem Cell Trial In Amyotrophic Lateral Sclerosis Published In Annals of Neurology

03/10/2014

Neuralstem Announces 2013 Financial Results

02/06/2014

Neuralstem President and CEO to Present NSI-566 Clinical Trials Program Update at BIO CEO & Investor Conference 2014

Live Webcast to Air on Tuesday, February 11, at 3:00 p.m. EST

01/14/2014

Neuralstem Appoints Catherine Sohn To Board Of Directors

01/13/2014

Updates on NSI-566 ALS Phase II - cSCI Phase I - Stroke Phase I/II, and NSI-189/MDD

1-25 26-28

Press Releases

2014 Archives

Information for Investors